Derrick D. Rowe
Partner
Dr. Derrick Rowe is a partner in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where his practice focuses on patent prosecution and counseling designed to help clients protect their intellectual property rights both domestically and internationally in the life sciences, biotechnology, molecular biology, pharmaceutical, diagnostic, and medical device fields.
Derrick has extensive experience and has developed his practice in view of his experience in private practice as well as an in-house counsel at a large pharmaceutical company where he provided patent, contract, regulatory, and strategic counseling for pharmaceuticals and vaccines (including for multiple marketed products and related strategic partnerships).
Derrick is the author or co-author of eight peer-reviewed scientific articles and several published legal articles. He has also served as speaker/panelist/moderator in multiple life science settings and has guest lectured at a U.S. law school on the topic of Intellectual Property Licensing Law.
Experience
Dr. Derrick Rowe is a partner in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where his practice focuses on patent prosecution and counseling designed to help clients protect their intellectual property rights both domestically and internationally in the life sciences, biotechnology, molecular biology, pharmaceutical, diagnostic, and medical device fields.
Derrick has extensive experience and has developed his practice in view of his experience in private practice as well as an in-house counsel at a large pharmaceutical company where he provided patent, contract, regulatory, and strategic counseling for pharmaceuticals and vaccines (including for multiple marketed products and related strategic partnerships).
Derrick is the author or co-author of eight peer-reviewed scientific articles and several published legal articles. He has also served as speaker/panelist/moderator in multiple life science settings and has guest lectured at a U.S. law school on the topic of Intellectual Property Licensing Law.
Education
- J.D., The George Washington University Law School
- Ph.D., Medical Sciences, University of South Florida
- M.S., Medical Sciences, University of South Florida
- B.S., Chemistry, University of Florida
Honors
- Named a “U.S. Rising Star” finalist in the Intellectual Property category for the LMG Life Sciences 2024 Americas Awards
Admissions
- Bar of the District of Columbia
- State Bar of Virginia
- U.S. Patent and Trademark Office
Credentials
Education
- J.D., The George Washington University Law School
- Ph.D., Medical Sciences, University of South Florida
- M.S., Medical Sciences, University of South Florida
- B.S., Chemistry, University of Florida
Honors
- Named a “U.S. Rising Star” finalist in the Intellectual Property category for the LMG Life Sciences 2024 Americas Awards
Admissions
- Bar of the District of Columbia
- State Bar of Virginia
- U.S. Patent and Trademark Office
Select Clients and Transactions
- Opus Genetics, Inc. in connection with its acquisition by Ocuphire Pharma, Inc.
- Tenaya Therapeutics in connection with its $50 million underwritten offering
- Metagenomi, Inc. in connection with its $93 million IPO
- BigHat Biosciences in connection with its research collaboration with AbbVie having an upfront payment of $30 million and up to approximately $325 million in aggregate research and development milestones, with the potential for further commercial milestones, as well as tiered royalties on net sales
- Metagenomi, Inc. in connection with its oversubscribed Series B financing totaling $275 million
- Tenaya Therapeutics in connection with its public offering
- Triumvira Immunologics, Inc. in connection with its $55 million in Series A funding
- Karius Inc. in connection with its $165 million in Series B funding
- Locus Biosciences in connection with its up-to-$818 million deal with J&J
- DNAlite in connection with its $1.5 million in Seed funding
- Cambridge Epigenetix Limited in connection with its $28.8 million Series B financing
- Medeor Therapeutics, Inc. in connection with its $57 million Series B financing
- NantHealth in connection with its IP strategy and its $91 million IPO
Matters
Select Clients and Transactions
- Opus Genetics, Inc. in connection with its acquisition by Ocuphire Pharma, Inc.
- Tenaya Therapeutics in connection with its $50 million underwritten offering
- Metagenomi, Inc. in connection with its $93 million IPO
- BigHat Biosciences in connection with its research collaboration with AbbVie having an upfront payment of $30 million and up to approximately $325 million in aggregate research and development milestones, with the potential for further commercial milestones, as well as tiered royalties on net sales
- Metagenomi, Inc. in connection with its oversubscribed Series B financing totaling $275 million
- Tenaya Therapeutics in connection with its public offering
- Triumvira Immunologics, Inc. in connection with its $55 million in Series A funding
- Karius Inc. in connection with its $165 million in Series B funding
- Locus Biosciences in connection with its up-to-$818 million deal with J&J
- DNAlite in connection with its $1.5 million in Seed funding
- Cambridge Epigenetix Limited in connection with its $28.8 million Series B financing
- Medeor Therapeutics, Inc. in connection with its $57 million Series B financing
- NantHealth in connection with its IP strategy and its $91 million IPO
Select Publications
- Co-author, “USPTO Proposes New Requirement for Terminal Disclaimers That Amounts to a Significant Change from Current Practice,” Wilson Sonsini Alert, May 15, 2024
- Co-author, “Opportunity for Innovative Companies to Shape U.S. Patent and Trademark Office Initiatives,” Wilson Sonsini Alert, May 2, 2024
- Co-author, “Newly Amended Chinese Implementing Rules for Patent Law and Guidelines for Patent Examination Bring Significant Changes to Patenting Strategy in China,” Wilson Sonsini Alert, April 3, 2024
- Co-author, “New York Redefines the Permissible Scope of Invention Assignment Provisions,” Wilson Sonsini Alert, March 6, 2024
- Co-author, “Bipartisan Legislation Seeks to Clarify Which Inventions Are Patent Eligible,” Intellectual Property & Law Journal, February 9, 2024
- Co-author, Draft Guidance Puts March-In Authority Pursuant to Bayh-Dole in the News Once Again,” Wilson Sonsini Alert, December 22, 2023
- Co-author, "EPO's '10-Day Rule' to End October 31, 2023, '7-Day Rule' to Begin November 1, 2023," Wilson Sonsini Alert, September 18, 2023
- Co-author, "HHS Names the First 10 Drugs for Medicare Price Negotiation," Wilson Sonsini Alert, September 5, 2023
- Co-author, "Major Change to European Patent System in 2023 to Impact Patent Owners' Portfolios," Wilson Sonsini Alert, October 21, 2022
- Co-author, "Prescription Drug Provisions in the Inflation Reduction Act of 2022," JD Supra, August 30, 2022
- Co-author, "Basics of the Bayh-Dole Act: FAQs," Wilson Sonsini Client Advisories, July 6, 2020
- Co-author, "Cures Revolution May Reshape Pharmaceutical Landscape," Law360, June 14, 2018
- Co-author, "USPTO Implements Post-Prosecution Pilot Program," Wilson Sonsini Alert, July 15, 2016
- Co-author, "The Retrospective Approach To Companion Diagnostics," Law360, June 5, 2015
- Co-author, "The Rise Of Companion Diagnostics In Personalized Medicine," Law360, June 5, 2015
Select Speaking Engagements
- Speaker, “Life Science Bootcamp with Wilson Sonsini: Insights on Business, IP, Corporate and Regulatory Challenges,” North Carolina Biotechnology Center, October 2023
- Speaker, “Entrepreneur Bootcamp,” Lab Central, October 2023
- Moderator, “Emerging Innovations: North Carolina’s Startup Showcase,” LaunchBio, Durham, North Carolina, May 2023
- Speaker, “Entrepreneur Bootcamp,” The George Washington University, February 2023
- Panelist, "FDA-PTO Roundtable," GW Law, January 21, 2022
- Guest lecturer, Intellectual Property Licensing Law, Temple University Beasley School of Law, 2021
- Moderator, "The Work Behind a Coronavirus Vaccine," Webinar, LaunchBio, April 16, 2020
- Moderator, "Non-Dilutive Funding for life Science Startups," LaunchBio, Durham, North Carolina, March 5, 2020
- Speaker, "Blockchain in Healthcare—Boom, Bogus, or Bust!" Society of Physician Entrepreneurs, Inova Personalized Health Accelerator, Fairfax, Virginia, May 9, 2018
- Speaker, "Recent Trends in Venture Markets and Financing," Technology Commercialization Office 2018 Start-Up Showcase, The George Washington University, Washington, D.C., April 17, 2018
Insights
Select Publications
- Co-author, “USPTO Proposes New Requirement for Terminal Disclaimers That Amounts to a Significant Change from Current Practice,” Wilson Sonsini Alert, May 15, 2024
- Co-author, “Opportunity for Innovative Companies to Shape U.S. Patent and Trademark Office Initiatives,” Wilson Sonsini Alert, May 2, 2024
- Co-author, “Newly Amended Chinese Implementing Rules for Patent Law and Guidelines for Patent Examination Bring Significant Changes to Patenting Strategy in China,” Wilson Sonsini Alert, April 3, 2024
- Co-author, “New York Redefines the Permissible Scope of Invention Assignment Provisions,” Wilson Sonsini Alert, March 6, 2024
- Co-author, “Bipartisan Legislation Seeks to Clarify Which Inventions Are Patent Eligible,” Intellectual Property & Law Journal, February 9, 2024
- Co-author, Draft Guidance Puts March-In Authority Pursuant to Bayh-Dole in the News Once Again,” Wilson Sonsini Alert, December 22, 2023
- Co-author, "EPO's '10-Day Rule' to End October 31, 2023, '7-Day Rule' to Begin November 1, 2023," Wilson Sonsini Alert, September 18, 2023
- Co-author, "HHS Names the First 10 Drugs for Medicare Price Negotiation," Wilson Sonsini Alert, September 5, 2023
- Co-author, "Major Change to European Patent System in 2023 to Impact Patent Owners' Portfolios," Wilson Sonsini Alert, October 21, 2022
- Co-author, "Prescription Drug Provisions in the Inflation Reduction Act of 2022," JD Supra, August 30, 2022
- Co-author, "Basics of the Bayh-Dole Act: FAQs," Wilson Sonsini Client Advisories, July 6, 2020
- Co-author, "Cures Revolution May Reshape Pharmaceutical Landscape," Law360, June 14, 2018
- Co-author, "USPTO Implements Post-Prosecution Pilot Program," Wilson Sonsini Alert, July 15, 2016
- Co-author, "The Retrospective Approach To Companion Diagnostics," Law360, June 5, 2015
- Co-author, "The Rise Of Companion Diagnostics In Personalized Medicine," Law360, June 5, 2015
Select Speaking Engagements
- Speaker, “Life Science Bootcamp with Wilson Sonsini: Insights on Business, IP, Corporate and Regulatory Challenges,” North Carolina Biotechnology Center, October 2023
- Speaker, “Entrepreneur Bootcamp,” Lab Central, October 2023
- Moderator, “Emerging Innovations: North Carolina’s Startup Showcase,” LaunchBio, Durham, North Carolina, May 2023
- Speaker, “Entrepreneur Bootcamp,” The George Washington University, February 2023
- Panelist, "FDA-PTO Roundtable," GW Law, January 21, 2022
- Guest lecturer, Intellectual Property Licensing Law, Temple University Beasley School of Law, 2021
- Moderator, "The Work Behind a Coronavirus Vaccine," Webinar, LaunchBio, April 16, 2020
- Moderator, "Non-Dilutive Funding for life Science Startups," LaunchBio, Durham, North Carolina, March 5, 2020
- Speaker, "Blockchain in Healthcare—Boom, Bogus, or Bust!" Society of Physician Entrepreneurs, Inova Personalized Health Accelerator, Fairfax, Virginia, May 9, 2018
- Speaker, "Recent Trends in Venture Markets and Financing," Technology Commercialization Office 2018 Start-Up Showcase, The George Washington University, Washington, D.C., April 17, 2018
Recent Insights
Alerts
The Inflation Reduction Act’s Medicare Price Negotiation Program: Two Years Later
The Inflation Reduction Act (the Act) of 2022 was controversial at the time the Act was signed into law and remains so. To date, multiple legal challenges have been asserted against the Act, with more expected in the future.
Learn More
Client Highlights
Wilson Sonsini Advises Opus Genetics on IP Matters Related to Acquisition by Ocuphire Pharma
On October 22, 2024, Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of patients with retinal and refractive eye disorders, announced the all-stock acquisition of Opus Genetics, Inc., a clinical-stage gene therapy company for inherited retinal diseases (IRDs). The merger creates a transformative biotech company committed to being a leader in the development of gene therapies for the treatment of IRDs. In connection with the merger, the combined company will be renamed Opus Genetics, Inc., effective October 23, 2024, and will trade on Nasdaq under the ticker symbol “IRD” effective October 24, 2024.
Learn More
Recent Events
Speaking Engagements
Georgetown OTM Seminar Series: What is a Patent Portfolio and Why Should You Care
Join Wilson Sonsini partner Derrick Rowe and the Georgetown University Office of Technology Commercialization for an insightful seminar designed for researchers, inventors, and graduate students who want to navigate the complex process of developing a patent portfolio to support their entrepreneurial endeavors.
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2024 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.